Recombinant multi-species NFYA protein for cell curture, in vitro study, in vivo study, benchmark, drug discovery & MOA research and positive control for the diagnosis

Genemedi produces recombinant Human, Cynomolgus/ Rhesus macaque, Rat, Mouse, Feline, Canine, Bovine, Equine NFYA protein for cell curture, in vitro study, in vivo study, benchmark, drug discovery & MOA research and positive control for the diagnosis.
The protein encoded by this gene is one subunit of a trimeric complex, forming a highly conserved transcription factor that binds to CCAAT motifs in the promoter regions in a variety of genes. Subunit A associates with a tight dimer composed of the B and C subunits, resulting in a trimer that binds to DNA with high specificity and affinity. The sequence specific interactions of the complex are made by the A subunit, suggesting a role as the regulatory subunit. In addition, there is evidence of post-transcriptional regulation in this gene product, either by protein degradation or control of translation. Further regulation is represented by alternative splicing in the glutamine-rich activation domain, with clear tissue-specific preferences for the two isoforms. [provided by RefSeq, Jul 2008]
The Alternative Names of target: CAAT box DNA-binding protein subunit A,CBF-A,CBF-B,Cbf-b,HAP2,NF-YA,NFYA,Nfya,Nuclear transcription factor Y subunit A (NF-YA),Nuclear transcription factor Y subunit alpha,SEZ-10,SEZ10

Target products collectionGo to NFYA products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)

pdfMSDSpdfCOApdfDatasheet

Product information

Catalog No. Product Name Species Reactivity
GM-Tg-hg-IP9106-Ag-1/ GM-Tg-hg-IP9106-Ag-2 Human NFYA protein Human
GM-Tg-rg-IP9106-Ag-1/ GM-Tg-rg-IP9106-Ag-2 Rat NFYA protein Rat
GM-Tg-mg-IP9106-Ag-1/ GM-Tg-mg-IP9106-Ag-2 Mouse NFYA protein Mouse
GM-Tg-cynog-IP9106-Ag-1/ GM-Tg-cynog-IP9106-Ag-2 Cynomolgus/Rhesus macaque NFYA protein Cynomolgus/ Rhesus macaque
GM-Tg-felg-IP9106-Ag-1/ GM-Tg-felg-IP9106-Ag-2 Feline NFYA protein Feline
GM-Tg-cang-IP9106-Ag-1/ GM-Tg-cang-IP9106-Ag-2 Canine NFYA protein Canine
GM-Tg-bovg-IP9106-Ag-1/ GM-Tg-bovg-IP9106-Ag-2 Bovine NFYA protein Bovine
GM-Tg-equg-IP9106-Ag-1/ GM-Tg-equg-IP9106-Ag-2 Equine NFYA protein Equine

Size： 1mg | 10mg | 100mg



Product Description

Catalog No. GM-Tg-hg-IP9106-Ag-1/ GM-Tg-hg-IP9106-Ag-2; GM-Tg-rg-IP9106-Ag-1/ GM-Tg-rg-IP9106-Ag-2;
GM-Tg-mg-IP9106-Ag-1/ GM-Tg-mg-IP9106-Ag-2; GM-Tg-cynog-IP9106-Ag-1/ GM-Tg-cynog-IP9106-Ag-2;
GM-Tg-felg-IP9106-Ag-1/ GM-Tg-felg-IP9106-Ag-2; GM-Tg-cang-IP9106-Ag-1/ GM-Tg-cang-IP9106-Ag-2;
GM-Tg-bovg-IP9106-Ag-1/ GM-Tg-bovg-IP9106-Ag-2; GM-Tg-equg-IP9106-Ag-1/ GM-Tg-equg-IP9106-Ag-2
Products Name NFYA protein
Species Human, Cynomolgus/ Rhesus macaque, rat, mouse, Feline, Canine, Bovine, Equine
Target Name NFYA
Protein Sub-location Introcelluar Protein
Isotypes Recombinant protein
Expression platform Mammalian cell
Bioactivity validation Affintiy&bioactivity validated by ELISA, cell culture validated.
Tag His
Products description Recombinant Human, Cynomolgus/ Rhesus macaque, Rat, Mouse, Feline, Canine, Bovine, Equine NFYA protein was expressed in mammalian cell expression system and is expressed with 6 HIS tag at the C-terminus for cell culture, ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).
Purity Purity: ≥95% (SDS-PAGE)
Application In vitro study, in vivo study, benchmark, positive control for the diagnosis. Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Formulation & Reconstitution Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4);
For PSB2, reconstituted with 0.9% sodium chloride;
For PBS, reconstituted with ddH2O.
Storage Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Reference






    About Gmab

    GDU
    GDU

    GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.
    Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.